Compare ACADIA Pharmaceuticals Inc. (ACAD) vs FMC Corp (FMC) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

FMC Corporation (FMC) trades at $10.24, down 2.1% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bearish technical signal with key support at $10 and resistance at $11. Fundamentally, the company faces significant challenges with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though valuation ratios like P/S of 0.4 and P/B of 0.8 appear attractive. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide technology.

The outlook remains cautious due to persistent profitability issues and revenue declines, with 2025 revenue dropping to $3.47B from $4.2B in 2024. While analyst consensus is mixed with a $11.60 price target suggesting modest upside, high debt levels and competitive pressures pose substantial risks. The company's focus on debt reduction through asset sales and external investments provides some stability, but turnaround execution is critical for sustained recovery.